Pazopanib trial data cannot support first-line use

Nature Reviews Urology

Volumn 7, Issue 6, 2010, Pages 307-308

  Jeldres, Claudio ^a   Sun, Maxine ^a   Perrotte, Paul ^a   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; EVEROLIMUS; INTERFERON; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; KIDNEY CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PYRIMIDINES; SULFONAMIDES;

EID: 77953570026     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.65     Document Type: Short Survey

References (9)

1. Rini, B. i. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
2. Motzer, R. J. et al. sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
3. escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 370, 2103-2111 (2007).
4. escudier, B. et al. sorafenib in advanced clearcell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
5. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
6. Motzer, R. J. et al. efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 372, 449-456 (2008).
7. sternberg, C. n. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase iii trial. J. Clin. Oncol. 28, 1061-1068 (2010).
8. Hutson, T. e. et al. efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 28, 475-480 (2010).
9. negrier, s. et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110, 2468-2477 (2007).